OSAKA -- Japanese drugmaker Shionogi expects to be able to sell its Xocova COVID-19 treatment in the U.S. in early 2025, part of a focus on overseas sales as public funding for coronavirus medications in Japan ends this month.
If the review by the U.S. Food and Drug Administration goes smoothly and the COVID pill is released, "the review process will speed up in other countries as well," Shionogi President and CEO Isao Teshirogi told Nikkei on Tuesday.
